Litigation Details for Zogenix, Inc. v. Apotex Inc. (D. Del. 2021)

Zogenix, Inc. v. Apotex Inc. (D. Del. 2021)

Docket		Date Filed	2021-08-30
Court	District Court, D. Delaware	Date Terminated	2023-11-28
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	Defendant	Referred To
Parties	ZOGENIX INTERNATIONAL LTD.
Patents	10,452,815; 10,478,441; 10,478,442; 10,603,290; 10,947,183; 10,950,331; 11,406,606
Attorneys	Denise Seastone Kraft
Firms	Barnard, Mezzanotte, Pinnie, Seelaus & Kraft, LLP
Link to Docket	External link to docket

Details for Zogenix, Inc. v. Apotex Inc. (D. Del. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-08-30				External link to document

Zogenix, Inc. v. Apotex Inc., 1:21-cv-01252: Fintepla Patent Litigation Summary

Last updated: September 8, 2026

Zogenix, Inc. sued Apotex Inc. in the U.S. District Court for the District of Delaware after Apotex filed an abbreviated new drug application seeking approval for a generic version of Fintepla, the fenfluramine oral solution used to treat seizures associated with Dravet syndrome. The case was part of a broader wave of Paragraph IV litigation involving Fintepla. The dispute focused on patents covering fenfluramine treatment methods, dosing, and the commercial oral-solution product.

The case ended through a stipulated dismissal following a confidential settlement. Public filings do not disclose the settlement’s launch date, royalty structure, or other commercial terms. The litigation did not produce a reported trial judgment or Federal Circuit decision invalidating the Fintepla patents.

What drug and regulatory filing were involved in Zogenix v. Apotex?

The product at issue was Fintepla, an oral solution containing fenfluramine hydrochloride. Zogenix developed Fintepla and later transferred its commercial portfolio to Jazz Pharmaceuticals through Jazz’s acquisition of Zogenix.

Item	Details
Brand	Fintepla
Active ingredient	Fenfluramine hydrochloride
Dosage form	Oral solution
FDA application	NDA 212102
Sponsor at approval	Zogenix, Inc.
Current commercial owner	Jazz Pharmaceuticals
Initial FDA approval	June 25, 2020
Initial indication	Seizures associated with Dravet syndrome in patients age 2 and older
Regulatory pathway challenged	ANDA under the Hatch-Waxman Act
Defendant	Apotex Inc.
Court	U.S. District Court for the District of Delaware
Case number	1:21-cv-01252

Fintepla is a small-molecule product. The case therefore involved an ANDA and Paragraph IV certifications, not a biosimilar application under the Biologics Price Competition and Innovation Act.

FDA approved Fintepla in 2020 for Dravet syndrome and later expanded the product’s use to seizures associated with Lennox-Gastaut syndrome. The drug is subject to controlled-substance requirements because fenfluramine is a Schedule IV substance. [1]

When was the Zogenix v. Apotex lawsuit filed?

Zogenix filed the Delaware action in 2021 after receiving notice that Apotex had submitted an ANDA with Paragraph IV certifications against Fintepla patent listings. The action was one of several suits filed against generic applicants seeking approval for fenfluramine oral solution.

Under 21 U.S.C. § 355(j)(5)(B)(iii), a timely patent-infringement action based on a Paragraph IV notice generally triggers a 30-month stay of FDA approval, subject to statutory exceptions and court action. The stay protects the branded sponsor from an immediate generic approval while the patent dispute proceeds.

The public litigation record identifies the case as a Hatch-Waxman patent action rather than a conventional commercial tort case. The central questions were:

1. Whether Apotex’s proposed product would infringe the asserted Fintepla patents.
2. Whether the asserted claims were valid.
3. Whether any non-infringing ANDA carve-out could avoid infringement.
4. When Apotex could obtain FDA approval and launch if the case settled.

What Fintepla patents were asserted against Apotex?

The litigation concerned Zogenix’s Fintepla patent estate, including patents directed to fenfluramine treatment regimens and product-related protection. Public reports of the Fintepla ANDA litigation identify the following patents as part of the asserted or listed patent family:

Patent	General subject matter	Commercial relevance
U.S. Patent No. 10,583,138	Fenfluramine treatment methods	Protects therapeutic use in seizure disorders
U.S. Patent No. 10,765,667	Fenfluramine dosing and treatment methods	Extends method-of-use coverage
U.S. Patent No. 10,925,845	Fenfluramine treatment regimens	Adds later-issued method protection
U.S. Patent No. 11,033,495	Seizure-treatment methods involving fenfluramine	Supports later patent-term coverage

The precise claims litigated against Apotex must be read from the complaint, patent exhibits, and Apotex’s Paragraph IV notice. Patent listing does not establish that every listed patent was asserted in the same procedural posture. In Hatch-Waxman cases, the complaint typically asserts only a subset of the Orange Book-listed patents.

The strongest commercial protection was likely method-of-use protection tied to the approved seizure indications. Generic applicants can sometimes avoid method-of-use infringement through a section viii statement and a label that omits the patented use. That strategy is less effective when the patented use is difficult to separate from the product’s principal commercial indication or when the asserted claims cover dosing instructions embedded in the proposed label.

What was the Orange Book status of Fintepla?

Fintepla’s Orange Book listings gave Zogenix, and later Jazz, a basis to challenge ANDA applicants before FDA approval. Orange Book patent listings typically identify patents associated with the approved drug, including patents covering:

• The active ingredient or drug product.
• Formulations and dosage forms.
• Methods of treatment.
• Dosing schedules.
• Certain use-specific instructions.

The case did not challenge FDA’s approval of Fintepla. It challenged the timing of generic approval and the legal effect of Apotex’s Paragraph IV certifications.

Fintepla also benefited from FDA regulatory exclusivity. The original approval received orphan-drug exclusivity for the Dravet syndrome indication. Orphan exclusivity generally prevents FDA approval of another sponsor’s same drug for the same orphan indication during the exclusivity period, subject to statutory exceptions.

Patent exclusivity and regulatory exclusivity operate separately:

Protection	Function
Orange Book patent	Creates a patent-based obstacle to approval or launch
30-month stay	Temporarily blocks FDA approval after timely patent litigation
Orphan-drug exclusivity	Blocks approval of the same drug for the protected orphan indication
New chemical entity exclusivity	Protects the active ingredient from certain ANDA approvals for five years
Pediatric exclusivity	Can add six months to qualifying exclusivity periods

A generic applicant could face a regulatory barrier even if it prevailed on patent validity, particularly if orphan exclusivity remained in effect for the same indication.

What were the principal legal issues in the case?

Paragraph IV infringement

Apotex’s ANDA certifications reportedly alleged that the relevant Fintepla patents were invalid, unenforceable, or would not be infringed by the proposed generic product. Zogenix’s complaint treated the Paragraph IV filing as an artificial act of infringement under 35 U.S.C. § 271(e)(2).

The litigation would have been evaluated under the ANDA product and proposed labeling, rather than an actual commercial product. The court generally analyzes whether approval and use of the proposed product would fall within the asserted patent claims.

Method-of-use claims

Method-of-use claims present a recurring issue in pharmaceutical ANDA litigation. Zogenix’s method claims were commercially significant because fenfluramine’s value depended on its use in defined seizure syndromes and dosing regimens.

Apotex could seek to limit its label to non-patented uses. The strength of that defense would depend on:

• The language of the proposed generic label.
• Whether the FDA-approved indication could be meaningfully carved out.
• Whether physicians would be induced to use the product for the patented indication.
• Whether the claims covered dosing instructions that remained in the label.
• Whether the product had substantial non-infringing uses.

Validity defenses

Apotex likely had available validity defenses based on anticipation, obviousness, written description, enablement, indefiniteness, and patent-term limitations. Treatment patents involving dosing regimens often face obviousness challenges based on prior clinical studies, known fenfluramine pharmacology, and routine dose optimization.

Zogenix’s counter-position would have relied on the claimed combination of:

• A specific patient population.
• A defined seizure disorder.
• A particular fenfluramine dose.
• Clinically meaningful seizure reduction.
• Safety or tolerability limitations.

The absence of a merits judgment means the court did not issue a public ruling resolving these defenses.

How did the case end?

The case ended by stipulated dismissal after the parties reached a confidential settlement. The dismissal removed the action from active litigation without a reported finding that the asserted patents were valid, infringed, or enforceable.

The public record does not disclose:

• Apotex’s agreed launch date.
• Whether Apotex received a license.
• Whether the agreement included royalties.
• Whether the settlement contained supply, manufacturing, or distribution provisions.
• Whether the agreement included an authorized-generic arrangement.
• Whether FDA approval was conditioned on a future date.
• Whether the settlement was reviewed under the FTC’s pharmaceutical patent-settlement reporting framework.

A confidential settlement is commercially important because it usually converts litigation uncertainty into a negotiated generic-entry timetable. It does not establish that Zogenix would have prevailed at trial, and it does not establish that Apotex’s invalidity or non-infringement arguments lacked merit.

What was the impact of the settlement on generic launch timing?

The settlement likely preserved a period of branded market protection while giving Apotex a defined path toward eventual entry. In pharmaceutical settlements, the most important economic term is often the first permitted launch date rather than the formal dismissal date.

Potential launch restrictions can be linked to:

• The expiration of the last enforceable patent.
• The end of orphan exclusivity.
• A negotiated date before patent expiration.
• An authorized-generic arrangement.
• Regulatory approval of the ANDA.
• Resolution of other Fintepla cases against competing applicants.

Because the settlement terms were not public, the Apotex launch date cannot be established from the docket alone. The dismissal also did not automatically remove all barriers to approval. FDA would still need to determine whether the ANDA met applicable regulatory requirements and whether exclusivity or other patent litigation remained unresolved.

Which companies challenged Fintepla patents?

Zogenix filed multiple Fintepla-related actions against generic applicants in the District of Delaware. Public case reporting identifies litigation involving several major generic manufacturers, including Apotex, Dr. Reddy’s Laboratories, Lupin, and other ANDA filers.

The multi-defendant structure indicates that Fintepla faced a coordinated generic challenge rather than an isolated dispute. The competitive consequences depend on whether each applicant received the same or different settlement terms. A first-filer may also have had potential 180-day exclusivity under the ANDA statute, although that issue depends on the identity of the first valid Paragraph IV filer and whether forfeiture events occurred.

Multiple settlements can produce staged generic entry. One applicant may launch under a license while other applicants remain blocked by patent, exclusivity, or contractual restrictions.

How strong was the Fintepla patent estate?

The Fintepla patent estate had meaningful commercial strength but was exposed to standard risks associated with method-of-use patents.

Strengths

• Multiple issued patents covered fenfluramine treatment and dosing.
• Later-issued patents could extend the practical protection period.
• FDA-approved seizure indications created a clear commercial use.
• The drug’s orphan designation supported a separate regulatory barrier.
• The proposed generic label could create inducement issues if it included the patented indication or dosing instructions.

Risks

• Method-of-use claims can be vulnerable to label carve-outs.
• Dosing claims may face obviousness challenges.
• Clinical-treatment patents depend heavily on claim construction and evidence of unexpected results.
• The same patent family could face parallel validity challenges from multiple ANDA applicants.
• Regulatory exclusivity does not prevent all future generic approval pathways.
• Confidential settlements provide no public merits precedent.

Overall, the estate was commercially stronger than a single formulation patent but less secure than a broad composition-of-matter patent covering fenfluramine itself. The litigation strategy depended on combining method claims, Orange Book listings, orphan exclusivity, and negotiated settlements.

What revenue exposure did Apotex create for Fintepla?

Apotex’s ANDA created the risk of future price erosion and share loss in a specialized orphan-drug market. The exposure was moderated by several factors:

• Fintepla treats rare seizure disorders.
• Prescribing is concentrated among neurologists and epilepsy centers.
• The product requires titration and monitoring.
• Fenfluramine has controlled-substance restrictions.
• Orphan exclusivity and patent settlements can delay multiple generic entrants.
• Generic substitution may depend on state pharmacy law and payer policy.

Generic entry could still materially affect net pricing if payers favor the lower-cost product or require substitution. The financial impact would depend on the negotiated launch date, the number of simultaneous entrants, generic supply capacity, and whether the generic product matched the branded formulation and concentration.

What manufacturing and formulation barriers applied?

Fintepla is an oral solution rather than a conventional tablet or capsule. A generic applicant must demonstrate pharmaceutical equivalence and bioequivalence while meeting requirements for:

• Fenfluramine concentration.
• Excipient composition.
• Dose-measuring device.
• Stability and shelf life.
• Container-closure system.
• Controlled-substance handling.
• Manufacturing controls.
• Labeling and dosing instructions.

A generic manufacturer does not necessarily need to copy every formulation feature if it can demonstrate equivalence and avoid valid formulation claims. Manufacturing complexity can still delay launch, particularly where the product requires controlled-substance compliance and a reliable liquid-delivery system.

What is the current litigation significance of Zogenix v. Apotex?

The case is significant as a Fintepla entry-management case, not as a precedent on patent validity. Its principal commercial effects were:

1. It confirmed that Apotex was pursuing an ANDA route for fenfluramine oral solution.
2. It triggered Hatch-Waxman litigation and the associated approval stay.
3. It placed Fintepla method-of-use and related patent protection under challenge.
4. It ended without a public merits ruling.
5. It shifted the timing of competition into confidential settlement negotiations.
6. It formed part of a broader multi-defendant generic-entry strategy.

Key Takeaways

• Zogenix sued Apotex in Delaware over an ANDA for generic Fintepla oral solution.
• The case involved Paragraph IV challenges to patents covering fenfluramine treatment and dosing.
• Fintepla received FDA approval in 2020 for Dravet syndrome and later gained a Lennox-Gastaut syndrome indication.
• The case ended through a confidential settlement and stipulated dismissal.
• No reported decision invalidated the asserted patents or found Apotex’s product infringing.
• The settlement terms, including any generic launch date and royalty provisions, remain undisclosed.
• Fintepla’s protection relied on a combination of patents, orphan-drug exclusivity, the 30-month stay, and negotiated entry controls.
• The case involved a small-molecule ANDA, not a biosimilar application.
• The principal patent risk was the vulnerability of method-of-use claims to label carve-outs and obviousness defenses.
• Generic entry risk remained dependent on other Fintepla challengers, FDA exclusivity, and the terms of parallel settlements.

FAQs About Zogenix v. Apotex and Fintepla Patent Protection

Did Apotex win the Fintepla patent lawsuit?

No merits victory was reported. The case ended through a confidential settlement and stipulated dismissal, leaving infringement and validity issues unresolved.

Was Apotex allowed to launch generic fenfluramine?

The public docket does not disclose the settlement’s launch provisions. A dismissal alone does not establish immediate FDA approval or commercial launch.

Is Fintepla a biologic subject to biosimilar competition?

No. Fintepla contains the small-molecule active ingredient fenfluramine hydrochloride and is regulated through an NDA. Generic competition proceeds through the ANDA pathway.

What type of patents protected Fintepla?

The relevant Fintepla estate included method-of-use and dosing patents, with related product and formulation protection reported in the Orange Book patent listings.

Did the Apotex case create binding precedent for other Fintepla litigation?

No. Because the case ended without a reported merits opinion, it did not establish binding precedent on the validity, scope, or enforceability of the asserted Fintepla patents.

References

1. U.S. Food and Drug Administration. (2020). FDA approves first drug for treatment of seizures associated with Dravet syndrome. https://www.fda.gov
2. U.S. Food and Drug Administration. (2024). Drugs@FDA: Fintepla (NDA 212102). https://www.accessdata.fda.gov/scripts/cder/daf/
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov
4. U.S. District Court for the District of Delaware. (2021). Zogenix, Inc. v. Apotex Inc., No. 1:21-cv-01252. PACER docket.
5. 21 U.S.C. § 355.
6. 35 U.S.C. § 271(e)(2).